NEW YORK — Pfizer on Tuesday might be putting its $3.4 billion consumer healthcare business on the sales block, noting that all scenarios would be considered during a strategic review of its options, which include a full or partial separation of the business from Pfizer through a spin-off, sale or other transaction.
Of course, Pfizer may ultimately determine to retain the business, the company added.
AUSTIN, Texas — Clarity Science, a division of Safe Harbor Compliance and Clinical Services, on Wednesday reported the results of the Institutional Review Board-approved Optimizing Patient Experience and Response to Topical Analgesics (OPERA) Study which evaluated patients with chronic pain who were treated with topical analgesics.
Overall results, published in the Journal of Pain Research, suggest that topical treatments may provide an effective and safer treatment alternative to opioids and prescription NSAIDs for the management of chronic pain.
CARLSBAD, Calif. — Oska Wellness on Tuesday announced two key additions to its executive leadership team with the hiring of Mike Regan as COO and Gary Acord as CFO.
"I'm delighted to announce that Mike and Gary are joining our team," stated Greg Houlgate, CEO/president Oska Wellness. "We're building great momentum here at Oska Wellness. Mike and Gary bring deep leadership experience at a time when we're focusing on its next phase of growth. This is an exciting time for the company."